Genolution Inc. - Asset Resilience Ratio

Latest as of September 2025: 3.80%

Genolution Inc. (225220) has an Asset Resilience Ratio of 3.80% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

₩3.79 Billion
≈ $2.57 Million USD Cash + Short-term Investments

Total Assets

₩99.84 Billion
≈ $67.66 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2016–2024)

This chart shows how Genolution Inc.'s Asset Resilience Ratio has changed over time. Check Genolution Inc. (225220) strategic investment index to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Genolution Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 225220 company net worth.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ₩0.00 0%
Short-term Investments ₩3.79 Billion 3.8%
Total Liquid Assets ₩3.79 Billion 3.80%

Asset Resilience Insights

  • Limited Liquidity: Genolution Inc. maintains only 3.80% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Genolution Inc. Industry Peers by Asset Resilience Ratio

Compare Genolution Inc.'s asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Tubize-Fin
BR:TUB
Biotechnology 0.05%
Verona Pharma plc
F:I9SA
Biotechnology 0.00%
Xiamen Amoytop Biotech Co Ltd
SHG:688278
Biotechnology 4.69%
Syndax Pharmaceuticals Inc
NASDAQ:SNDX
Biotechnology 46.79%
Neuren Pharmaceuticals Ltd
AU:NEU
Biotechnology 90.43%
Vor Biopharma Inc
NASDAQ:VOR
Biotechnology 63.47%
Chengdu Kanghua Biological Products
SHE:300841
Biotechnology 1.19%
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
Biotechnology 4.35%

Annual Asset Resilience Ratio for Genolution Inc. (2016–2024)

The table below shows the annual Asset Resilience Ratio data for Genolution Inc..

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 31.20% ₩33.21 Billion
≈ $22.51 Million
₩106.45 Billion
≈ $72.14 Million
-6.49pp
2023-12-31 37.69% ₩42.75 Billion
≈ $28.97 Million
₩113.44 Billion
≈ $76.88 Million
-2.82pp
2022-12-31 40.51% ₩46.37 Billion
≈ $31.42 Million
₩114.45 Billion
≈ $77.56 Million
-7.87pp
2021-12-31 48.38% ₩45.93 Billion
≈ $31.13 Million
₩94.94 Billion
≈ $64.34 Million
-10.06pp
2020-12-31 58.44% ₩48.96 Billion
≈ $33.18 Million
₩83.77 Billion
≈ $56.77 Million
+30.02pp
2019-12-31 28.42% ₩3.82 Billion
≈ $2.59 Million
₩13.43 Billion
≈ $9.10 Million
-18.57pp
2018-12-31 46.99% ₩5.21 Billion
≈ $3.53 Million
₩11.10 Billion
≈ $7.52 Million
+1.21pp
2017-12-31 45.78% ₩2.15 Billion
≈ $1.46 Million
₩4.71 Billion
≈ $3.19 Million
-12.50pp
2016-12-31 58.28% ₩2.33 Billion
≈ $1.58 Million
₩3.99 Billion
≈ $2.71 Million
--
pp = percentage points

About Genolution Inc.

KQ:225220 Korea Biotechnology
Market Cap
$15.82 Million
₩23.34 Billion KRW
Market Cap Rank
#25788 Global
#1919 in Korea
Share Price
₩1292.00
Change (1 day)
-0.31%
52-Week Range
₩1030.00 - ₩2590.00
All Time High
₩10300.23
About

Genolution Inc. manufactures and sells IVD medical instruments in South Korea and internationally. Its products are primarily focused on molecular diagnostics, ribonucleic acid interference (RNAi) services, and double-stranded RNA (dsRNA) synthesis technology. The company offers Nextractor NX-Duo, Nextractor NX-32N/45N, Nextractor NX-Jr, Nextractor NX-24SA, NGS library preparation equipment, DNA/… Read more